Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Exemestane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exemestane SCHEMBL178041 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL172893 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL2233503 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL19452231 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL13794245 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL6215 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL1781618 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL172860 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL21698489 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| SCHEMBL13301017 | 0.92 | CYP19A1 (0.84) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190343844-A1 | METHODS FOR THE TREATMENT OF BREAST CANCER | SYNDAX PHARMACEUTICALS, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10226472-B2 | Methods for the treatment of breast cancer | SYNDAX PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20140378420-A1 | METHODS FOR THE TREATMENT OF BREAST CANCER | SYNDAX PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378420-A1 | METHODS FOR THE TREATMENT OF BREAST CANCER | SYNDAX PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| WO-2014179738-A1 | METHODS FOR THE TREATMENT OF CANCER | SYNDAX PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| EP-2142561-B9 | PROCESS FOR PREPARING AROMATASE INHIBITORS | SCINOPHARM TAIWAN LTD (TW) | 2014-02-19 | — | — | EP | disclosed |
| US-8541609-B2 | Exemestane and its intermediates and methods of making the same | CEDARBURG PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2142561-B1 | PROCESS FOR PREPARING AROMATASE INHIBITORS | SCINOPHARM TAIWAN LTD (TW) | 2013-06-26 | — | — | EP | disclosed |
| WO-2013033656-A1 | METHODS FOR THE TREATMENT OF BREAST CANCER | SYNDAX PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-8288571-B2 | Process for preparing aromatiase inhibitor exemestane | CADILA HEALTHCARE LIMITED (IN) | 2012-10-16 | — | — | US | disclosed |
| US-20110118488-A1 | PROCESS FOR OBTAINING 6-ALKYLIDENANDROST-1, 4-DIENE-3-ONE | CRYSTAL PHARMA, S.A. (ES) | 2011-05-19 | — | — | US | disclosed |
| US-20100311993-A1 | PROCESS FOR PREPARING AROMATIASE INHIBITOR EXEMESTANE | CADILA HEALTHCARE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100311993-A1 | PROCESS FOR PREPARING AROMATIASE INHIBITOR EXEMESTANE | CADILA HEALTHCARE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| WO-2009093262-A2 | PROCESS FOR PREPARING AROMATASE INHIBITOR EXEMESTANE | CADILA HEALTHCARE LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009077454-A1 | PROCESS FOR OBTAINING 6-ALKYLIDENANDROST-1, 4-DIENE-3-ONE | CRYSTAL PHARMA, S.A. (ES) | 2009-06-25 | — | — | WO | disclosed |
| EP-2070943-A1 | Process for obtaining 6-Alkylidenandrost-1,4-diene-3one | Crystal Pharma, S.A. (ES) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008137048-A1 | PROCESS FOR PREPARING AROMATASE INHIBITORS | SCINOPHARM TAIWAN, LTD. (TW) | 2008-11-13 | — | — | WO | disclosed |
| US-20080275259-A1 | Process for preparing aromatase inhibitors | SCINOPHARM TAIWAN, LTD (TW) | 2008-11-06 | — | — | US | disclosed |
| US-20080275259-A1 | Process for preparing aromatase inhibitors | SCINOPHARM TAIWAN, LTD (TW) | 2008-11-06 | — | — | US | disclosed |
| US-20080234505-A1 | Exemestane and Its Intermediates and Methods of Making the Same | CEDARBURG PHARMACEUTICALS, INC (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118488-A1 | PROCESS FOR OBTAINING 6-ALKYLIDENANDROST-1, 4-DIENE-3-ONE | SRD5A1, SRD5A2, NR5A1 | CYP19A1 6/4885KDM4E 2350/4885ALDH1A1 120/4885 |
| US-20100311993-A1 | PROCESS FOR PREPARING AROMATIASE INHIBITOR EXEMESTANE | CYP19A1, POR, CYP17A1 | CYP19A1 1/4885KDM4E 263/4885ALDH1A1 349/4885 |
| US-20080275259-A1 | Process for preparing aromatase inhibitors | CYP19A1, HSD17B11, CYP17A1 | CYP19A1 1/4885KDM4E 1317/4885ALDH1A1 659/4885 |
| US-20190343844-A1 | METHODS FOR THE TREATMENT OF BREAST CANCER | CYP19A1, HDAC1, HSD17B11 | CYP19A1 1/4885KDM4E 247/4885ALDH1A1 314/4885 |
| US-20080234505-A1 | Exemestane and Its Intermediates and Methods of Making the Same | CYP19A1, ESR1, CYP21A2 | CYP19A1 1/4885KDM4E 1865/4885ALDH1A1 1440/4885 |
| US-10226472-B2 | Methods for the treatment of breast cancer | CYP19A1, HDAC1, HSD17B11 | CYP19A1 1/4885KDM4E 247/4885ALDH1A1 314/4885 |
| US-20140378420-A1 | METHODS FOR THE TREATMENT OF BREAST CANCER | CYP19A1, HDAC1, HSD17B11 | CYP19A1 1/4885KDM4E 247/4885ALDH1A1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.